Immune checkpoint inhibition has in many ways revolutionized cancer therapy by blocking primarily the inhibitory molecules, PD-1 or CTLA-4, that are expressed by exhausted effector T cells or Treg cells (4). This evidence concerns the gene CTLA4 and cancer.